Pediatric Cancer
Although genetic screening plus surveillance for children with certain genetic variants could reduce cancer deaths by 7.8 percent before age 20, health systems may not find such programs cost effective.
NCCN Publishes First Set of Guidelines for Wilms Tumor
In addition to treatment regimens, the guidelines include recommendations for molecular testing and surveillance for patients with predisposition syndromes.
MSK Team Explores Clinical Utility of Germline Testing for Pediatric Cancer Patients
The researchers found that 18 percent of pediatric cancer patients tested with MSK-IMPACT harbored one or more inherited risk mutation.
In a recently published study, researchers found NTRK fusions were more common in pediatric than adult tumors and testing for them helped diagnose rare tumors.
FDA Approves Pfizer's Xalkori for Pediatric ALK-Positive Lymphoma
The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.